NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,758.18 mln
Float127 mln
Earnings Date05/06/2026
EPS
2.30
Solid
P / E
9.65
Undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-0.82
Highly suspicious
1-Year Forecast
31.70
Exceptional upside
Relative Strength
63
/ 100
Outperforming
Business Description
ACADIA Pharmaceuticals is a US-based drug development company focused on treating neurological and rare diseases. Its two approved products, NUPLAZID and DAYBUE, address psychosis in Parkinson's disease and symptoms of Rett syndrome respectively. The company has several additional treatments in various stages of clinical trials, targeting conditions such as Alzheimer's disease psychosis, major depressive disorder, essential tremor, and Huntington's disease. Founded in 1993 and based in San Diego, California, ACADIA also works with partners like Neuren Pharmaceuticals and Stoke Therapeutics to expand its pipeline of specialized medicines.
